Inflammatory biomarkers in osteoarthritis

Osteoarthritis and Cartilage

Volumn 23, Issue 11, 2015, Pages 1890-1896

  Daghestani, H N ^a   Kraus, V B ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarker; Inflammation; Osteoarthritis

Indexed keywords

ADIPOCYTOKINE; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CLUSTERIN; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4 BINDING PROTEIN; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C7; COMPLEMENT COMPONENT C9; COMPLEMENT FACTOR H; HORMONE; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LAMININ GAMMA1; MICRORNA 132; MITOGEN ACTIVATED PROTEIN KINASE; PUMA PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INDUCIBLE GENE 6; UNCLASSIFIED DRUG; UNINDEXED DRUG; CYTOKINE; RNA;

AGE RELATED MACULAR DEGENERATION; ALZHEIMER DISEASE; ATHEROSCLEROSIS; CARTILAGE CELL; DISEASE SEVERITY; DNA REPAIR; DOWN REGULATION; FOXO GENE; FOXO1 GENE; GENE EXPRESSION; GENETICS; GENOMICS; HUMAN; IL 1BETA GENE; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; JNK GENE; KNEE OSTEOARTHRITIS; MACROPHAGE; MICROARRAY ANALYSIS; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PUMA GENE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIAL FLUID; TGF BETA GENE; UPREGULATION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; METABOLISM;

BIOMARKERS; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; OSTEOARTHRITIS, KNEE; RNA; SYNOVIAL FLUID;

EID: 84945243507     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2015.02.009     Document Type: Review

References (123)

1. Sellam J., Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 2010, 6(11):625-635.
2. Takahashi T., Nagai H., Seki H., Fukuda M. Relationship between joint effusion, joint pain, and protein levels in joint lavage fluid of patients with internal derangement and osteoarthritis of the temporomandibular joint. J Oral Maxillofac Surg 1999, 57(10):1187-1193. discussion 1193-4.
3. Orlowsky E.W., Kraus V.B. The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive. J Rheumatol 2015 Jan 15, pii: jrheum.140382. [Epub ahead of print].
4. Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products 2012.
5. Paving the Way for Personalized Medicine 2013, U.S. Department of Health and Human Services Food and Drug Administration.
6. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease 2011, National Academies Press, Washington, D.C.
7. FDA approves Kalydeco to treat rare form of cystic fibrosis. Breakthrough Therapy Targets Defective Protein 2012, U.S. Food and Drug Administration.
8. FDA approves new treatment for hepatitis C virus. FDA News Release 2013, U.S. Department of Health and Human Services Food and Drug Administration.
9. FDA approves Sovaldi for chronic hepatitis C. FDA News Release 2013, U.S. Department of Health and Human Services Food and Drug Administration.
10. FDA approves first combination pill to treat hepatitis C. FDA News Release 2014, U.S. Department of Health and Human Services Food and Drug Administration.
11. Riyazi N., Slagboom E., de Craen A.J., Meulenbelt I., Houwing-Duistermaat J.J., Kroon H.M., et al. Association of the risk of osteoarthritis with high innate production of interleukin-1beta and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation. Arthritis Rheum 2005, 52(5):1443-1450.
12. Goekoop R.J., Kloppenburg M., Kroon H.M., Frolich M., Huizinga T.W., Westendorp R.G., et al. Low innate production of interleukin-1beta and interleukin-6 is associated with the absence of osteoarthritis in old age. Osteoarthr Cartil 2010, 18(7):942-947.
13. Han L., Lee H.S., Yoon J.H., Choi W.S., Park Y.G., Nam S.W., et al. Association of IL-17A and IL-17F single nucleotide polymorphisms with susceptibility to osteoarthritis in a Korean population. Gene 2014, 533(1):119-122.
14. Hamalainen S., Solovieva S., Vehmas T., Leino-Arjas P., Hirvonen A. Variations in the TNFalpha gene and their interactions with the IL4R and IL10 genes in relation to hand osteoarthritis. BMC Musculoskelet Disord 2014, 15:311.
15. Yigit S., Inanir A., Tekcan A., Tural E., Ozturk G.T., Kismali G., et al. Significant association of interleukin-4 gene intron 3 VNTR polymorphism with susceptibility to knee osteoarthritis. Gene 2014, 537(1):6-9.
16. Kraus V.B. Preclinical osteoarthritis. Rhuematology 2014, 1498-1547. Mosby Elsevier, Philadelphia, PA. 6th edn. M.C. Hochberg, A.J. Silman, J.S. Smolen, M.E. Weinblatt, M.H. Weisman (Eds.).
17. Grice E.A., Segre J.A. Interaction of the microbiome with the innate immune response in chronic wounds. Adv Exp Med Biol 2012, 946:55-68.
18. Li S., Dong G., Moschidis A., Ortiz J., Benakanakere M.R., Kinane D.F., et al. P. gingivalis modulates keratinocytes through FOXO transcription factors. PLoS One 2013, 8(11):e78541.
19. Hameedaldeen A., Liu J., Batres A., Graves G.S., Graves D.T. FOXO1, TGF-beta regulation and wound healing. Int J Mol Sci 2014, 15(9):16257-16269.
20. Akasaki Y., Hasegawa A., Saito M., Asahara H., Iwamoto Y., Lotz M.K. Dysregulated FOXO transcription factors in articular cartilage in aging and osteoarthritis. Osteoarthr Cartil 2014, 22(1):162-170.
21. Akasaki Y., Alvarez-Garcia O., Saito M., Carames B., Iwamoto Y., Lotz M.K. FoxO transcription factors support oxidative stress resistance in human chondrocytes. Arthritis Rheumatol 2014, 66(12):3349-3358.
22. Dell'accio F., De Bari C., Eltawil N.M., Vanhummelen P., Pitzalis C. Identification of the molecular response of articular cartilage to injury, by microarray screening: Wnt-16 expression and signaling after injury and in osteoarthritis. Arthritis Rheum 2008, 58(5):1410-1421.
23. Lu H., Hou G., Zhang Y., Dai Y., Zhao H. c-Jun transactivates Puma gene expression to promote osteoarthritis. Mol Med Rep 2014, 9(5):1606-1612.
24. Luyten F.P., Tylzanowski P., Lories R.J. Wnt signaling and osteoarthritis. Bone 2009, 44(4):522-527.
25. Rai M.F., Schmidt E.J., McAlinden A., Cheverud J.M., Sandell L.J. Molecular insight into the association between cartilage regeneration and ear wound healing in genetic mouse models: targeting new genes in regeneration. G3 (Bethesda) 2013, 3(11):1881-1891.
26. Attur M., Belitskaya-Levy I., Oh C., Krasnokutsky S., Greenberg J., Samuels J., et al. Increased interleukin-1beta gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. Arthritis Rheum 2011, 63(7):1908-1917.
27. Okuhara A., Nakasa T., Shibuya H., Niimoto T., Adachi N., Deie M., et al. Changes in microRNA expression in peripheral mononuclear cells according to the progression of osteoarthritis. Mod Rheumatol 2012, 22(3):446-457.
28. Murata K., Yoshitomi H., Tanida S., Ishikawa M., Nishitani K., Ito H., et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2010, 12(3):R86.
29. Marshall K.W., Zhang H., Yager T.D., Nossova N., Dempsey A., Zheng R., et al. Blood-based biomarkers for detecting mild osteoarthritis in the human knee. Osteoarthr Cartil 2005, 13(10):861-871.
30. Barton G.M. A calculated response: control of inflammation by the innate immune system. J Clin Invest 2008, 118(2):413-420.
31. Fernandez-Madrid F., Karvonen R.L., Teitge R.A., Miller P.R., An T., Negendank W.G. Synovial thickening detected by MR imaging in osteoarthritis of the knee confirmed by biopsy as synovitis. Magn Reson Imaging 1995, 13(2):177-183.
32. Ayral X., Pickering E.H., Woodworth T.G., Mackillop N., Dougados M. Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis - results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthr Cartil 2005, 13(5):361-367.
33. Kraus V.B., McDaniel G., Huebner J.L., Stabler T., Pieper C., Coleman R.E., et al. Direct in vivo evidence of activated macrophages in human osteoarthritis. Osteoarthr Cartil 2013, 21. (Supplement, April).
34. Daghestani H.N., Pieper C.F., Kraus V.B. Soluble macrophage biomarkers indicate inflammatory phenotypes in patients with knee osteoarthritis. Arthritis Rheumatol 2014 Dec 29, [Epub ahead of print]. 10.1002/art.39006.
35. Roemer F.W., Guermazi A., Felson D.T., Niu J., Nevitt M.C., Crema M.D., et al. Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: the MOST study. Ann Rheum Dis 2011, 70(10):1804-1809.
36. Bondeson J., Wainwright S.D., Lauder S., Amos N., Hughes C.E. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006, 8(6):R187.
37. Denoble A.E., Huffman K.M., Stabler T.V., Kelly S.J., Hershfield M.S., McDaniel G.E., et al. Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci USA 2011, 108(5):2088-2093.
38. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440(7081):237-241.
39. Orlowsky E.W., Stabler T.V., Montell E., Verges J., Kraus V.B. Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis?. BMC Musculoskelet Disord 2014, 15:318.
40. Chhana A., Callon K.E., Pool B., Naot D., Gamble G.D., Dray M., et al. The effects of monosodium urate monohydrate crystals on chondrocyte viability and function: implications for development of cartilage damage in gout. J Rheumatol 2013, 40(12):2067-2074.
41. Bondeson J. Activated synovial macrophages as targets for osteoarthritis drug therapy. Curr Drug Targets 2010, 11(5):576-585.
42. Tsuneyoshi Y., Tanaka M., Nagai T., Sunahara N., Matsuda T., Sonoda T., et al. Functional folate receptor beta-expressing macrophages in osteoarthritis synovium and their M1/M2 expression profiles. Scand J Rheumatol 2012, 41(2):132-140.
43. Low P.S., Henne W.A., Doorneweerd D.D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008, 41(1):120-129.
44. Xia W., Hilgenbrink A.R., Matteson E.L., Lockwood M.B., Cheng J.X., Low P.S. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 2009, 113(2):438-446.
45. Renkema G.H., Boot R.G., Au F.L., Donker-Koopman W.E., Strijland A., Muijsers A.O., et al. Chitotriosidase, a chitinase, and the 39-kDa human cartilage glycoprotein, a chitin-binding lectin, are homologues of family 18 glycosyl hydrolases secreted by human macrophages. Eur J Biochem 1998, 251(1-2):504-509.
46. Nyirkos P., Golds E.E. Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period. Biochem J 1990, 269(1):265-268.
47. Hakala B.E., White C., Recklies A.D. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993, 268(34):25803-25810.
48. Volck B., Johansen J.S., Stoltenberg M., Garbarsch C., Price P.A., Ostergaard M., et al. Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthr Cartil 2001, 9(3):203-214.
49. Sarma J.V., Ward P.A. The complement system. Cell Tissue Res 2011, 343(1):227-235.
50. Hsueh M.F., Onnerfjord P., Kraus V.B. Biomarkers and proteomic analysis of osteoarthritis. Matrix Biol 2014, 39:56-66.
51. Gobezie R., Kho A., Krastins B., Sarracino D.A., Thornhill T.S., Chase M., et al. High abundance synovial fluid proteome: distinct profiles in health and osteoarthritis. Arthritis Res Ther 2007, 9(2):R36.
52. Fernandez-Puente P., Mateos J., Fernandez-Costa C., Oreiro N., Fernandez-Lopez C., Ruiz-Romero C., et al. Identification of a panel of novel serum osteoarthritis biomarkers. J Proteome Res 2011, 10(11):5095-5101.
53. Wang Q., Rozelle A.L., Lepus C.M., Scanzello C.R., Song J.J., Larsen D.M., et al. Identification of a central role for complement in osteoarthritis. Nat Med 2011, 17(12):1674-1679.
54. Clark A.G., Jordan J.M., Vilim V., Renner J.B., Dragomir A.D., Luta G., et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999, 42(11):2356-2364.
55. Verma P., Dalal K. Serum cartilage oligomeric matrix protein (COMP) in knee osteoarthritis: a novel diagnostic and prognostic biomarker. J Orthop Res 2013, 31(7):999-1006.
56. Fernandes F.A., Pucinelli M.L., da Silva N.P., Feldman D. Serum cartilage oligomeric matrix protein (COMP) levels in knee osteoarthritis in a Brazilian population: clinical and radiological correlation. Scand J Rheumatol 2007, 36(3):211-215.
57. Neidhart M., Hauser N., Paulsson M., DiCesare P.E., Michel B.A., Hauselmann H.J. Small fragments of cartilage oligomeric matrix protein in synovial fluid and serum as markers for cartilage degradation. Br J Rheumatol 1997, 36(11):1151-1160.
58. Lohmander L.S., Saxne T., Heinegard D.K. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis 1994, 53(1):8-13.
59. Otteby K.E., Holmquist E., Saxne T., Heinegard D., Hesselstrand R., Blom A.M. Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis. Arthritis Res Ther 2013, 15(6):R215.
60. Happonen K.E., Saxne T., Aspberg A., Morgelin M., Heinegard D., Blom A.M. Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis. Arthritis Rheum 2010, 62(12):3574-3583.
61. Molenaar E.T., Voskuyl A.E., Familian A., van Mierlo G.J., Dijkmans B.A., Hack C.E. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein. Arthritis Rheum 2001, 44(5):997-1002.
62. Nydegger U.E., Zubler R.H., Gabay R., Joliat G., Karagevrekis C.H., Lambert P.H., et al. Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity. J Clin Invest 1977, 59(5):862-868.
63. Niculescu F., Rus H. The role of complement activation in atherosclerosis. Immunol Res 2004, 30(1):73-80.
64. Niculescu F., Rus H.G., Vlaicu R. Activation of the human terminal complement pathway in atherosclerosis. Clin Immunol Immunopathol 1987, 45(2):147-155.
65. Aiyaz M., Lupton M.K., Proitsi P., Powell J.F., Lovestone S. Complement activation as a biomarker for Alzheimer's disease. Immunobiology 2012, 217(2):204-215.
66. Eikelenboom P., Hack C.E., Rozemuller J.M., Stam F.C. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch B Cell Pathol Incl Mol Pathol 1989, 56(4):259-262.
67. Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 1992, 89(21):10016-10020.
68. Scholl H.P., Charbel Issa P., Walier M., Janzer S., Pollok-Kopp B., Borncke F., et al. Systemic complement activation in age-related macular degeneration. PLoS One 2008, 3(7):e2593.
69. Johnson L.V., Leitner W.P., Staples M.K., Anderson D.H. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res 2001, 73(6):887-896.
70. Du Clos T.W., Mold C. Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fcgamma receptors. Curr Opin Organ Transpl 2011, 16(1):15-20.
71. Du Clos T.W. Function of C-reactive protein. Ann Med 2000, 32(4):274-278.
72. Kalogeropoulos A.P., Tang W.H., Hsu A., Felker G.M., Hernandez A.F., Troughton R.W., et al. High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. J Card Fail 2014, 20(5):319-326.
73. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375(9709):132-140. Emerging Risk Factors Collaboration.
74. Andersson B.A., Lewin F., Lundgren J., Nilsson M., Rutqvist L.E., Lofgren S., et al. Plasma tumor necrosis factor-alpha and C-reactive protein as biomarker for survival in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol 2014, 140(3):515-519.
75. Vermeire S., Van Assche G., Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004, 10(5):661-665.
76. Pearle A.D., Scanzello C.R., George S., Mandl L.A., DiCarlo E.F., Peterson M., et al. Elevated high-sensitivity C-reactive protein levels are associated with local inflammatory findings in patients with osteoarthritis. Osteoarthr Cartil 2007, 15(5):516-523.
77. Jin X., Beguerie J.R., Zhang W., Blizzard L., Otahal P., Jones G., et al. Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis 2013 Dec 20, [Epub ahead of print]. 10.1136/annrheumdis-2013-204494.
78. Sowers M., Jannausch M., Stein E., Jamadar D., Hochberg M., Lachance L. C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthr Cartil 2002, 10(8):595-601.
79. Kraus V.B., Stabler T.V., Luta G., Renner J.B., Dragomir A.D., Jordan J.M. Interpretation of serum C-reactive protein (CRP) levels for cardiovascular disease risk is complicated by race, pulmonary disease, body mass index, gender, and osteoarthritis. Osteoarthr Cartil 2007, 15(8):966-971.
80. Kerkhof H.J., Bierma-Zeinstra S.M., Castano-Betancourt M.C., de Maat M.P., Hofman A., Pols H.A., et al. Serum C reactive protein levels and genetic variation in the CRP gene are not associated with the prevalence, incidence or progression of osteoarthritis independent of body mass index. Ann Rheum Dis 2010, 69(11):1976-1982.
81. Liles W.C., Van Voorhis W.C. Review: nomenclature and biologic significance of cytokines involved in inflammation and the host immune response. J Infect Dis 1995, 172(6):1573-1580.
82. Commins S.P., Borish L., Steinke J.W. Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol 2010, 125(2 Suppl 2):S53-S72.
83. Hanada T., Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002, 13(4-5):413-421.
84. Rot A., von Andrian U.H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004, 22:891-928.
85. Seruga B., Zhang H.B., Bernstein L.J., Tannock I.F. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008, 8(11):887-899.
86. Stannus O., Jones G., Cicuttini F., Parameswaran V., Quinn S., Burgess J., et al. Circulating levels of IL-6 and TNF-alpha are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults. Osteoarthr Cartil 2010, 18(11):1441-1447.
87. Guo H., Luo Q., Zhang J., Lin H., Xia L., He C. Comparing different physical factors on serum TNF-alpha levels, chondrocyte apoptosis, caspase-3 and caspase-8 expression in osteoarthritis of the knee in rabbits. Joint Bone Spine 2011, 78(6):604-610.
88. Chevalier X., Ravaud P., Maheu E., Baron G., Rialland A., Vergnaud P., et al. Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial. Ann Rheum Dis 2014 May 9, [Epub ahead of print]. 10.1136/annrheumdis-2014-205348.
89. Simao A.P., Almeida T.M., Mendonca V.A., Santos S.A., Gomes W.F., Coimbra C.C., et al. Soluble TNF receptors are produced at sites of inflammation and are inversely associated with self-reported symptoms (WOMAC) in knee osteoarthritis. Rheumatol Int 2014, 34(12):1759-1763.
90. Milner C.M., Day A.J. TSG-6: a multifunctional protein associated with inflammation. J Cell Sci 2003, 116(Pt 10):1863-1873.
91. Wisniewski H.G., Maier R., Lotz M., Lee S., Klampfer L., Lee T.H., et al. TSG-6: a TNF-, IL-1-, and LPS-inducible secreted glycoprotein associated with arthritis. J Immunol 1993, 151(11):6593-6601.
92. Wisniewski H.G., Colon E., Liublinska V., Karia R.J., Stabler T.V., Attur M., et al. TSG-6 activity as a novel biomarker of progression in knee osteoarthritis. Osteoarthr Cartil 2014, 22(2):235-241.
93. Vangsness C.T., Burke W.S., Narvy S.J., MacPhee R.D., Fedenko A.N. Human knee synovial fluid cytokines correlated with grade of knee osteoarthritis-a pilot study. Bull NYU Hosp Jt Dis 2011, 69(2):122-127.
94. Beekhuizen M., Gierman L.M., van Spil W.E., Van Osch G.J., Huizinga T.W., Saris D.B., et al. An explorative study comparing levels of soluble mediators in control and osteoarthritic synovial fluid. Osteoarthr Cartil 2013, 21(7):918-922.
95. Livshits G., Zhai G., Hart D.J., Kato B.S., Wang H., Williams F.M., et al. Interleukin-6 is a significant predictor of radiographic knee osteoarthritis: the Chingford Study. Arthritis Rheum 2009, 60(7):2037-2045.
96. King L.K., March L., Anandacoomarasamy A. Obesity & osteoarthritis. Indian J Med Res 2013, 138:185-193.
97. Salih S., Sutton P. Obesity, knee osteoarthritis and knee arthroplasty: a review. BMC Sports Sci Med Rehabil 2013, 5(1):25.
98. Distel E., Cadoudal T., Durant S., Poignard A., Chevalier X., Benelli C. The infrapatellar fat pad in knee osteoarthritis: an important source of interleukin-6 and its soluble receptor. Arthritis Rheum 2009, 60(11):3374-3377.
99. Miller G.D., Nicklas B.J., Loeser R.F. Inflammatory biomarkers and physical function in older, obese adults with knee pain and self-reported osteoarthritis after intensive weight-loss therapy. J Am Geriatr Soc 2008, 56(4):644-651.
100. Helmark I.C., Mikkelsen U.R., Borglum J., Rothe A., Petersen M.C., Andersen O., et al. Exercise increases interleukin-10 levels both intraarticularly and peri-synovially in patients with knee osteoarthritis: a randomized controlled trial. Arthritis Res Ther 2010, 12(4):R126.
101. Zou Y., Li Y., Lu L., Lin Y., Liang W., Su Z., et al. Correlation of fractalkine concentrations in serum and synovial fluid with the radiographic severity of knee osteoarthritis. Ann Clin Biochem 2013, 50(Pt 6):571-575.
102. Xu Q., Sun X.C., Shang X.P., Jiang H.S. Association of CXCL12 levels in synovial fluid with the radiographic severity of knee osteoarthritis. J Investig Med 2012, 60(6):898-901.
103. Li L., Jiang B.E. Serum and synovial fluid chemokine ligand 2/monocyte chemoattractant protein 1 concentrations correlates with symptomatic severity in patients with knee osteoarthritis. Ann Clin Biochem 2014 Jul 8, pii: 0004563214545117. [Epub ahead of print].
104. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006, 116(6):1494-1505.
105. Yla-Herttuala S., Lipton B.A., Rosenfeld M.E., Sarkioja T., Yoshimura T., Leonard E.J., et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991, 88(12):5252-5256.
106. Al-Suhaimi E.A., Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res 2013, 18:12.
107. Toussirot E., Streit G., Wendling D. The contribution of adipose tissue and adipokines to inflammation in joint diseases. Curr Med Chem 2007, 14(10):1095-1100.
108. Kang E.H., Lee Y.J., Kim T.K., Chang C.B., Chung J.H., Shin K., et al. Adiponectin is a potential catabolic mediator in osteoarthritis cartilage. Arthritis Res Ther 2010, 12(6):R231.
109. Hui W., Litherland G.J., Elias M.S., Kitson G.I., Cawston T.E., Rowan A.D., et al. Leptin produced by joint white adipose tissue induces cartilage degradation via upregulation and activation of matrix metalloproteinases. Ann Rheum Dis 2012, 71(3):455-462.
110. Hu P.F., Chen W.P., Tang J.L., Bao J.P., Wu L.D. Apelin plays a catabolic role on articular cartilage: in vivo and in vitro studies. Int J Mol Med 2010, 26(3):357-363.
111. Perruccio A.V., Mahomed N.N., Chandran V., Gandhi R. Plasma adipokine levels and their association with overall burden of painful joints among individuals with hip and knee osteoarthritis. J Rheumatol 2014, 41(2):334-337.
112. White R.T., Damm D., Hancock N., Rosen B.S., Lowell B.B., Usher P., et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem 1992, 267(13):9210-9213.
113. Yusuf E., Ioan-Facsinay A., Bijsterbosch J., Klein-Wieringa I., Kwekkeboom J., Slagboom P.E., et al. Association between leptin, adiponectin and resistin and long-term progression of hand osteoarthritis. Ann Rheum Dis 2011, 70(7):1282-1284.
114. Dumond H., Presle N., Terlain B., Mainard D., Loeuille D., Netter P., et al. Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 2003, 48(11):3118-3129.
115. Karvonen-Gutierrez C.A., Harlow S.D., Mancuso P., Jacobson J., Mendes de Leon C.F., Nan B. Association of leptin levels with radiographic knee osteoarthritis among a cohort of midlife women. Arthritis Care Res Hob 2013, 65(6):936-944.
116. Berry P.A., Jones S.W., Cicuttini F.M., Wluka A.E., Maciewicz R.A. Temporal relationship between serum adipokines, biomarkers of bone and cartilage turnover, and cartilage volume loss in a population with clinical knee osteoarthritis. Arthritis Rheum 2011, 63(3):700-707.
117. Laiguillon M.C., Houard X., Bougault C., Gosset M., Nourissat G., Sautet A., et al. Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis. Arthritis Res Ther 2014, 16(1):R38.
118. Duan Y., Hao D., Li M., Wu Z., Li D., Yang X., et al. Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis. Rheumatol Int 2012, 32(4):985-990.
119. Salem M.L., Hossain M.S., Nomoto K. Mediation of the immunomodulatory effect of beta-estradiol on inflammatory responses by inhibition of recruitment and activation of inflammatory cells and their gene expression of TNF-alpha and IFN-gamma. Int Arch Allergy Immunol 2000, 121(3):235-245.
120. Sowers M.R., McConnell D., Jannausch M., Buyuktur A.G., Hochberg M., Jamadar D.A. Estradiol and its metabolites and their association with knee osteoarthritis. Arthritis Rheum 2006, 54(8):2481-2487.
121. Hashimoto S., Rai M.F., Janiszak K.L., Cheverud J.M., Sandell L.J. Cartilage and bone changes during development of post-traumatic osteoarthritis in selected LGXSM recombinant inbred mice. Osteoarthr Cartil 2012, 20(6):562-571.
122. Heard B.J., Rosvold J.M., Fritzler M.J., El-Gabalawy H., Wiley J.P., Krawetz R.J. A computational method to differentiate normal individuals, osteoarthritis and rheumatoid arthritis patients using serum biomarkers. J R Soc Interface 2014, 11(97):20140428.
123. Hunter D.J., Nevitt M., Losina E., Kraus V. Biomarkers for osteoarthritis: current position and steps towards further validation. Best Pract Res Clin Rheumatol 2014, 28(1):61-71.